Prices as of 2026/10/30 close
Company comparison · Mid-Tier Pharma & Drug Discovery
Ono is the largest by revenue at ¥515.8B, followed by Nippon Shinyaku (¥170.8B), JCR (¥40.3B) and Peptide Dream (¥18.5B).
Nippon Shinyaku has the highest operating margin at 20.8%, 47.9 points above the lowest, Peptide Dream (-27.1%).
Revenue growth in the latest results: JCR +21.9%, Nippon Shinyaku +6.6%, Ono +5.9%, Peptide Dream −60.3%. For next year, JCR guides for the fastest operating profit growth (+98.2%).
Peptide Dream pays the most on average (¥11.7M), ¥3.50M more than JCR (¥8.19M).
Over the past year the shares moved Ono +26.8%, Nippon Shinyaku +6.8%, JCR −5.7%, Peptide Dream −28.4%.
Head-to-head wins16 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Ono aheadOno 3 : Nippon Shinyaku 0 : JCR 0 : Peptide Dream 0
Revenue: Ono ¥515.8B / Nippon Shinyaku ¥170.8B / JCR ¥40.3B / Peptide Dream ¥18.5B
ProfitabilityInvestors
Nippon Shinyaku aheadOno 1 : Nippon Shinyaku 2 : JCR 0 : Peptide Dream 0
Operating margin: Ono 17.9% / Nippon Shinyaku 20.8% / JCR 1.4% / Peptide Dream −27.1%
GrowthInvestors
EvenOno 1 : Nippon Shinyaku 0 : JCR 2 : Peptide Dream 2
Revenue growth (YoY): Ono +5.9% / Nippon Shinyaku +6.6% / JCR +21.9% / Peptide Dream −60.3%
Stock & balance sheetInvestors
EvenOno 1 : Nippon Shinyaku 0 : JCR 0 : Peptide Dream 1
Share price, 1 year: Ono +26.8% / Nippon Shinyaku +6.8% / JCR −5.7% / Peptide Dream −28.4%
Pay & workforceJob seekers
Nippon Shinyaku aheadOno 0 : Nippon Shinyaku 2 : JCR 0 : Peptide Dream 1
Average salary: Ono ¥10.2M / Nippon Shinyaku ¥9.19M / JCR ¥8.19M / Peptide Dream ¥11.7M
| Metric | Ono | Nippon Shinyaku | JCR | Peptide Dream |
|---|---|---|---|---|
| Revenue | ◎¥515.8B | ¥170.8B | ¥40.3B | ¥18.5B |
| Operating profit | ◎¥92.2B | ¥35.5B | ¥555M | −¥5.0B |
| Net income | ◎¥69.8B | ¥29.7B | ¥2.2B | −¥3.7B |
| Metric | Ono | Nippon Shinyaku | JCR | Peptide Dream |
|---|---|---|---|---|
| Operating margin | 17.9% | ◎20.8% | 1.4% | −27.1% |
| Net margin | 13.5% | ◎17.4% | 5.4% | −20.2% |
| ROE | — | — | 4.6% | — |
| Revenue per employee | ◎¥149M | ¥91M | ¥43M | ¥118M |
| Metric | Ono | Nippon Shinyaku | JCR | Peptide Dream |
|---|---|---|---|---|
| Revenue growth (YoY) | +5.9% | +6.6% | ◎+21.9% | −60.3% |
| Operating profit growth (YoY) | ◎+54.4% | +0.1% | — | — |
| Revenue CAGRlast 5 years | +10.8% | +7.0% | — | ◎+18.6% |
| Guidance: revenue growthnext FY plan | −11.8% | +17.1% | +13.3% | ◎+72.8% |
| Guidance: op. profit growthnext FY plan | +1.9% | +7.1% | ◎+98.2% | — |
| Metric | Ono | Nippon Shinyaku | JCR | Peptide Dream |
|---|---|---|---|---|
| Share price, 1 year | ◎+26.8% | +6.8% | −5.7% | −28.4% |
| Share price, 3 months | −8.2% | −1.7% | +7.9% | ◎+19.2% |
| P/E (trailing)lower = cheaper | — | — | 30.4x | — |
| Equity ratio | — | — | 43.4% | — |
| Share price (close) | ¥2,256 | ¥3,436 | ¥544 | ¥1,117 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Ono | Nippon Shinyaku | JCR | Peptide Dream |
|---|---|---|---|---|
| Average salary | ¥10.2M | ¥9.19M | ¥8.19M | ◎¥11.7M |
| Starting salary (monthly) | ¥273,000 | ◎¥279,000 | ¥230,000 | — |
| Average tenure | 16.9 yrs | ◎17.2 yrs | 9.5 yrs | 5.3 yrs |
| Average age | 44.2 | 41.4 | 41.4 | 39.7 |
| Employees | 3,464 | 1,876 | 937 | 157 |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥2,256+26.8% (1Y)
Ono +26.8% over 1Y. Compared: Nippon Shinyaku +6.8%, JCR -5.7%, Peptide Dream -28.4%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Ono1 segments
Nippon Shinyaku2 segments
JCR1 segments
Peptide Dream2 segments
AAverage annual salary from the securities filings: Peptide Dream ¥11.7M, Ono ¥10.2M, Nippon Shinyaku ¥9.19M, JCR ¥8.19M. Peptide Dream pays the most. Averages also depend on staff age and job mix, so check the average age too (Ono 44.2, Nippon Shinyaku 41.4, JCR 41.4, Peptide Dream 39.7).
ARevenue in the latest results: Ono ¥515.8B, Nippon Shinyaku ¥170.8B, JCR ¥40.3B, Peptide Dream ¥18.5B. Ono is the largest by revenue at ¥515.8B, followed by Nippon Shinyaku (¥170.8B), JCR (¥40.3B) and Peptide Dream (¥18.5B).
AOperating margins: Nippon Shinyaku 20.8%, Ono 17.9%, JCR 1.4%, Peptide Dream -27.1%. Nippon Shinyaku turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Ono +26.8%, Nippon Shinyaku +6.8%, JCR −5.7%, Peptide Dream −28.4%. Ono has risen the most.
Comparing 4 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
